LivaNova PLC(NASDAQ:LIVN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 3, 2016. Company reported revenue of $321.00M. Analysts estimated a revenue of $312.64M. Earnings per share were $0.87. Analysts had estimated an EPS of $0.72.
Several Insider Transactions has been reported to the SEC. On May 25, 2016, Daniel Jeffrey Moore (director) sold 1,000 shares at $50.07 per share price.Also, On May 23, 2016, Hugh M Morrison (director) sold 3,600 shares at $48.00 per share price.On May 10, 2016, Alfred J Novak (director) sold 4,000 shares at $51.12 per share price, according to the Form-4 filing with the securities and exchange commission.
LivaNova PLC is a United Kingdom-based medical technology company. The Company focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company operates under three business units: Cardiac Rhythm Management Cardiac Surgery and Neuromodulation. The Company provides solutions for patients healthcare professionals and healthcare systems. The Company’s Cardiac Rhythm Management unit focuses on Bradyarrhythmia Tachyarrhythmia Heart Failure Arrhythmia Assessment and Electrophysiology. The Company’s Cardiac Surgery unit focuses on Aortic Mitral Perfusion Cannulae Minimally Invasive Cardiac Surgery and Pediatric. Its Neuromodulation unit focuses on providing medical device solutions for people affected by treatment-resistant epilepsy depression heart failure and other chronic disorders. Its products include PARADYM RF VOLTA SMARTVIEW SOLO SMART CONNECT INSPIRE XTRA MINIMALLY INVASIVE CARDIAC SURGERY CANNULAE and PEDIATRIC CANNULAE among others.